ClinicalTrials.gg
RecruitingNCT06676410Codivir®Updated Nov 6, 2024

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

A Phase 2 interventional study of ICF and Eligibility Assessment in HIV and HIV Infection, sponsored by Code Pharma. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Code Pharma · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2023, registered Oct 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in HIV Infections with a site in Brazil — 12 open to participants now, 17 under way, 5 of them phase 3. HIV Infections · Brazil.

Planned enrollment
103rd of 116
40 · median 255
Started
2023
with 3 others
Phase 2
24 of 142
3 open now
Primary completion
2024-12
later than 3 of 16 live
Registered
137th of 142
by date

Among the 142 studies in HIV Infections with a site in Brazil, this one is the 103rd largest by planned enrollment of the 116 interventional ones that give a count, is one of 4 that started in 2023, is one of 24 in phase 2, reaches primary completion later than 3 of the 16 other live ones, and was the 137th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

12 of the 142 studies in HIV Infections with a site in Brazil are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in HIV Infections with a site in Brazil, or all of them as a file.
02

Study summary

The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step.

At V0 (W0, D0) all participants will start the antiretroviral treatment described above.

From V0 (W0, D0) to V6 (W12, D84) participants randomized to Codivir® will receive Codivir® as complementary therapy to the above antiretrovirals on alternate days (every other day).

At V6 (W12, D84) treatment with Codivir® will end. At V7 (W24, D168) participation in the study will end. Viral load will be monitored during the study. In case of failure, participation in the study will be discontinued and the participant will be referred to receive the best treatment available for their case.

03

Conditions studied

  • HIV
  • HIV Infection

Keywords

  • HIV
  • AIDS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female sex;
  2. Age ≥ 18 years;
  3. infection confirmed by serology (Ab for HIV1/HIV2) and HIV1/HIV2 RNA test;
  4. Naive for antiretroviral treatment;
  5. Viral load > 1,000 and \< 50,000 copies/mL;
  6. CD4 T lymphocyte (CD4) cell count >350 cells/mm3;
  7. Body weight at V -1 > 50 Kg;
  8. Signature of the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, lactation or plan to become pregnant;
  2. \< 18.5 kg/m2 at screening;
  3. Coinfection with (HBSAg +) or ;
  4. Any Grade 3 or 4 abnormality according to the Division of AIDS (DAIDS)* rating scale;
  5. Any significant acute illness within 1 week before V0.
  6. Use of any immunomodulatory therapy (including interferon), systemic , or systemic chemotherapy within 4 weeks of screening;
  7. Active or ongoing malignancy;
  8. Changes in safety tests: \< 1000 u/L; \< 9.0 gm/dl; \< 75,000 u/L; creatinine > 1.5 mg/dl, direct > 85 μmol/l, or ALT > 2.5 X ;
  9. Potential allergy or to components of the Codivir® formulation.
  10. Participation in another clinical trial within 12 months of screening.
  11. Any medical condition that makes the participant unsuitable for the study or increases the risk of participation at the discretion of the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Codivir®

    The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step. In Weeks 0-24, all participants will receive: * Single solid formulation (in 1 tablet) 1x/day with: * Tenofovir (TDF) 300 mg * Lamivudine (3TC) 300 mg * Darunavir (DRV) 800 mg, 1x/day * Ritonavir (RTV) 100 mg, 1x/day From V0 (W0, D0) to V6 (W12, D84) participants randomized to Codivir® will receive Codivir® as complementary therapy to the above antiretrovirals on alternate days (every other day). At V6 (week 12) treatment with Codivir® will end.

    Other: ICF · Behavioral: Eligibility Assessment · Other: Demographic data · Diagnostic Test: Weight, height and BMI · Other: Vital Signs · Diagnostic Test: Medical evaluation · Diagnostic Test: Safety exam · Diagnostic Test: Pregnancy test · Diagnostic Test: Serology · Other: Randomization · Diagnostic Test: Apoptosis markers · Diagnostic Test: Cell activation markers · Diagnostic Test: Inflammation markers · Diagnostic Test: Proviral DNA: · Diagnostic Test: HIV-specific antibodies · Diagnostic Test: HIV viral load (RNA) · Behavioral: Codivir® Training · Drug: Dispensing Codivir® · Other: Codivir® Accounting · Other: Concomitant medication · Other: Adverse events

  • Active comparator
    Antiretrovirals (ARTs)

    In Weeks 0-24, all participants will receive: * Single solid formulation (in 1 tablet) 1x/day with: * Tenofovir (TDF) 300 mg * Lamivudine (3TC) 300 mg * Darunavir (DRV) 800 mg, 1x/day * Ritonavir (RTV) 100 mg, 1x/day

    Other: ICF · Behavioral: Eligibility Assessment · Other: Demographic data · Diagnostic Test: Weight, height and BMI · Other: Vital Signs · Diagnostic Test: Medical evaluation · Diagnostic Test: Safety exam · Diagnostic Test: Pregnancy test · Diagnostic Test: Serology · Other: Randomization · Diagnostic Test: Apoptosis markers · Diagnostic Test: Cell activation markers · Diagnostic Test: Inflammation markers · Diagnostic Test: Proviral DNA: · Diagnostic Test: HIV-specific antibodies · Diagnostic Test: HIV viral load (RNA) · Other: Concomitant medication · Other: Adverse events · Drug: Antiretrovirals

Interventions

  • OtherICF

    Application of Informed Consent Form.

  • BehavioralEligibility Assessment

    Assessment of inclusion, exclusion and discontinuation criteria.

  • OtherDemographic data

    Collection of demographic data.

  • Diagnostic testWeight, height and BMI

    Weight and height measurement and body mass index calculation.

  • OtherVital Signs

    HR, BP and FR and T°, in addition to oximetry.

  • Diagnostic testMedical evaluation

    Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.

  • Diagnostic testSafety exam

    Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.

  • Diagnostic testPregnancy test

    β-HCG in urine in non-sterile women

  • Diagnostic testSerology

    HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).

  • OtherRandomization

    Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group

  • Diagnostic testApoptosis markers

    Caspases and Annexin V.

  • Diagnostic testCell activation markers

    PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR

  • Diagnostic testInflammation markers

    ultrasensitive CRP, D-dimer.

  • Diagnostic testProviral DNA:

    Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.

  • Diagnostic testHIV-specific antibodies

    Anti-HIV-1 specific antibody titers in plasma.

  • Diagnostic testHIV viral load (RNA)

    Performed on plasma.

  • BehavioralCodivir® Training

    The participant is trained to self-inject Codivir®

  • DrugDispensing Codivir®

    the participant receives Codivir®

  • OtherCodivir® Accounting

    The Codivir® used since the last visit is accounted for

  • OtherConcomitant medication

    Record of concomitant medications used.

  • OtherAdverse events

    Collection and recording of adverse events.

  • DrugAntiretrovirals

    Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination. * Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro. * Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS. * Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS). * Single solid formulation (in 1 tablet) 1x/day with: * Tenofovir (TDF) 300 mg * Lamivudine (3TC) 300 mg * Darunavir (DRV) 800 mg, 1x/day * Ritonavir (RTV) 100 mg, 1x/day

06

What researchers measure

Primary outcomes

  1. Variation between V-2 (baseline) and V6 (W12) in relation to the following parameter: • Estimated viral reservoir size by total blood proviral DNA.

    Time frame: 12 weeks

  2. Variation between V-2 (baseline) and V6 (W12) in relation to the following parameter: CD4+ blood count

    Time frame: 12 weeks

Secondary outcomes

  1. Variation between baseline visit and visit 7 (W24) in relation to the following parameter : Estimated viral reservoir size by total proviral DNA

    Time frame: 24 weeks

  2. Variation between baseline visit and visit 7 (W24) in relation to the following parameter : CD4+ count.

    Time frame: 24 weeks

  3. Variation between baseline visit and visit 7 (W24) in relation to the following parameter: apoptosis markers

    Time frame: 24 weeks

  4. Variation between baseline visit and visit 7 (W24) in relation to the following parameter : Cell activation markers

    Time frame: 24 weeks

  5. Variation between baseline visit and visit 7 (W24) in relation to the following parameter: Inflammation markers

    Time frame: 24 weeks

  6. Variation between baseline visit and visit 7 (W24) in relation to the following parameter: Quantitative Proviral (DNA)

    Time frame: 24 weeks

  7. Variation between baseline visit and visit 7 (W24) in relation to the following parameter: HIV viral load (RNA)

    Time frame: 24 weeks

  8. - Comparison of viral load curves from all visits between the two groups.

    Time frame: 24 weeks

  9. Codivir® safety by comparison of treatment-emergent adverse events in both groups.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • RDSS Research Center
    São Paulo, 04037-030, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 17 months is below that.

Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Nov 6, 2024
StartActual
Jul 20, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06676410
Lead sponsor
Code Pharma
Collaborators
Galilee CBR
Responsible party
Sponsor
First posted
Nov 6, 2024
Start date
Jul 20, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Nov 6, 2024

Study contacts

Nadya Lisovoder, MD
Contact
nadyal@galilee-cbr.com
0524753435

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion